About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGPhase 2NCT07333183

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung ...

Lead sponsor: Pulmovant, Inc.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Pulmovant

CONTACT

+1-919-462-1310 clinicaltrials@pulmovant.com

Sponsors

Lead Sponsor

Pulmovant, Inc.

This study is an open-label study with an extension. The study consists of 2 periods: an open label treatment period (16 weeks) and an extension (beyond 16 weeks). Participants will receive mosliciguat in the 16-week treatment period. All participants who complete the 16-week treatment period may continue to participate in the extension period where all participants will receive mosliciguat.

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participants willing and able to provide informed consent
•Participants on inhaled treprostinil
•Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:
•1. Idiopathic interstitial pneumonia (IIP)
•2. Chronic hypersensitivity pneumonitis
•3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \< 70% of predicted
•Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).
•Ability to perform 6MWD ≥100 meters.

Exclusion Criteria

•Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).
•Exacerbation of underlying lung disease within 28 days prior to randomization.
•Initiation of pulmonary rehabilitation within 28 days prior to randomization.
•Receiving \>10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
•History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.
•Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.

Related studies

Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung Diseases

NCT07615504 · Interstitial Lung Disease (ILD)

RECRUITINGPhase 1

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

NCT07552779 · Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), and more

RECRUITINGPhase 1/2

Feasibility of Semaglutide in Advanced Lung Disease

NCT05746039 · Obesity, Interstitial Lung Disease, and more

Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.

NCT07537517 · Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension (PH), and more

NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases

NCT05722340 · Lung Diseases, Interstitial

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 22, 2026Terms

Trial snapshot

StatusRECRUITING

PhasePHASE2

Enrollment20

Start dateDec 2025

Last updatedApr 22, 2026

Condition

Pulmonary Hypertension Interstitial Lung Disease (ILD)Lung Diseases Vascular Diseases Cardiovascular Diseases+1 more

Locations shown

Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC

Kissimmee, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 22, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions